Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore

References

• Teng GG, Ang LW, Saag KG, et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis. 2012;71:924–928.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B* 5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19:704–709.
   PubMed Web of Science ®Google Scholar
• Mahar PD, Wasiak J, Hii B, et al. A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres. Burns. 2014;40:1245–1254.
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272–1285.
   PubMed Web of Science ®Google Scholar
• Dong D, Tan-Koi WC, Teng GG, et al. Cost–effectiveness analysis of genotyping for HLA-B* 5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. Pharmacogenomics. 2015;16:1781–1793.
   PubMed Web of Science ®Google Scholar
• Duong TA, Valeyrie-Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390:1996–2011.
   PubMed Web of Science ®Google Scholar
• Pillai NE, Okada Y, Saw WY, et al. Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations. Hum Mol Genet. 2014;23:4443–4451.
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2010;11:973–987.
   PubMed Web of Science ®Google Scholar
• Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose‐dependent oxypurinol‐specific T cell response. Clin Exp Allergy. 2013;43:1246–1255.
   PubMed Web of Science ®Google Scholar
• Fam AG, Dunne SM, Iazzetta J, et al. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. 2001;44:231–238.
   PubMed Web of Science ®Google Scholar
• Jung JW, Kim DK, Park HW, et al. An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. Genet Med. 2015;17:807–814.
   PubMed Web of Science ®Google Scholar
• Drug prices. Singapore: Ministry of Health; 2016. [2020 Mar 3]. Available from: https://www.moh.gov.sg/content/moh_web/home/pressRoom/Parliamentary_QA/2016/drug-prices.html
   Google Scholar
• Department of Statistics Singapore. Available from: https://www.singstat.gov.sg/find-data/search-by-theme/populatio/death-and-life-expectancy/latest-data
   Google Scholar
• Khanna D, Khanna PP, Fitzgerald JD, et al. American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64:1447–1461.
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29–42.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Jr Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–2461.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Jr Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty‐eight–day, multicenter, phase II, randomized, double‐blind, placebo‐controlled, dose‐response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52:916–923.
   PubMed Web of Science ®Google Scholar
• Huang X, Du H, Gu J, et al. An allopurinol‐controlled, multicenter, randomized, double‐blind, parallel between‐group, comparative study of febuxostat in C hinese patients with gout and hyperuricemia. Int J Rheum Dis. 2014;17:679–686.
   PubMed Web of Science ®Google Scholar
• Reinders M, Haagsma C, Jansen TTA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis. 2009;68:892–897.
   PubMed Web of Science ®Google Scholar
• Reinders M, Van Roon E, Jansen TTA, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51–56.
   PubMed Web of Science ®Google Scholar
• Saag KG, Whelton A, Becker MA, et al. Impact of febuxostat on renal function in gout patients with moderate‐to‐severe renal impairment. Arthritis Rheumatol. 2016;68:2035–2043.
   PubMed Web of Science ®Google Scholar
• Schumacher HR, Jr Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis Rheum. 2008;59:1540–1548.
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378:1200–1210.
   PubMed Web of Science ®Google Scholar
• Xu S, Liu X, Ming J, et al. A phase 3, multicenter, randomized, allopurinol‐controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. Int J Rheum Dis. 2015;18:669–678.
   PubMed Web of Science ®Google Scholar
• Yu K, Lai J, Hsu P, et al. Safety and efficacy of oral febuxostat for treatment of HLA-B* 5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. Scand J Rheumatol. 2016;45:304–311.
   PubMed Web of Science ®Google Scholar
• Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2014;15:863–897.
   Web of Science ®Google Scholar
• Plumpton CO, Alfirevic A, Pirmohamed M, et al. Cost effectiveness analysis of HLA-B* 58: 01 genotyping prior to initiation of allopurinol for gout. Rheumatology. 2017;56:1729–1739.
   PubMed Web of Science ®Google Scholar
• Tayar JH, Lopez‐Olivo MA, Suarez‐Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev. 2012;CD008653.
   PubMed Web of Science ®Google Scholar
• IMS. A health economic assessment of febuxostat in the management of gout. Data on File. Version No 1.0. 2007.
   Google Scholar
• Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol. 2013;40:872–876.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, MacDONALD PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273–1282.
   PubMed Web of Science ®Google Scholar
• Saokaew S, Tassaneeyakul W, Maenthaisong R, et al. Cost-effectiveness analysis of HLA-B* 5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. PloS One. 2014;9:e94294.
   PubMed Web of Science ®Google Scholar
• Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123:1160–1165.
   PubMed Web of Science ®Google Scholar
• Schöpf E, Stühmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol. 1991;127:839–842.
   PubMedGoogle Scholar
• Somkrua R, Chaiyakunapruk N, Tassaneeyakul W. PSS14 what cost of HLA-B* 5801 genotyping would be cost efective for the prevention of allopurinol-induced Stevens Johnson syndrome/toxic epidermal necrolysis in THAILAND: analyses using a decision-analytic model. Value Health. 2010;13:A564–A565.
   Web of Science ®Google Scholar
• Hofhuis JG, Spronk PE, van Stel HF, et al. The impact of severe sepsis on health-related quality of life: a long-term follow-up study. Anesth Analg. 2008;107:1957–1964.
   PubMed Web of Science ®Google Scholar
• Oster C, Willebrand M, Dyster-Aas J, et al. Validation of the EQ-5D questionnaire in burn injured adults. Burns. 2009;35:723–732.
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier J. Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods. Medical Care. 2012;50:452–459.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110:1412–1419.
   PubMed Web of Science ®Google Scholar
• Lee H, Walsh S, Creamer D. Long‐term complications of Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow‐up. Br J Dermatol. 2017;177:924–935.
   PubMed Web of Science ®Google Scholar
• Ke CH, Chung WH, Wen YH, et al. Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol. 2017;44:835–843.
   PubMed Web of Science ®Google Scholar
• Jutkowitz E, Choi HK, Pizzi LT, et al. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med. 2014;161:617–626.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Díaz-Torné C, Carcedo D. Cost-effectiveness analysis of febuxostat in patients with gout in Spain. Journal of Medical Economics. 2016;19:604–610.
   PubMed Web of Science ®Google Scholar
• Choi H, Neogi T, Stamp L, et al. New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated food and drug administration public safety alert. Arthritis Rheumatol. 2018;70:1702–1709.
   PubMed Web of Science ®Google Scholar
• Chua XHJ, Lim S, Lim FP, et al. Factors influencing medication adherence in patients with gout: a descriptive correlational study. J Clin Nurs. 2018;27:e213–e22.
   PubMed Web of Science ®Google Scholar
• Lin LW, Teng GG, Lim AYN, et al. Cost‐effectiveness of an adherence‐enhancing intervention for gout based on real‐world data. Int J Rheum Dis. 2019;22:545–554.
   PubMed Web of Science ®Google Scholar
• Park DJ, Kang JH, Lee JW, et al. Cost‐Effectiveness Analysis of HLA–B5801 Genotyping in the Treatment of Gout Patients With Chronic Renal Insufficiency in Korea. Arthritis Care Res. 2015;67:280–287.
   Web of Science ®Google Scholar